# Cero Therapeutics Holdings, Inc.: financial statements, quarterly

CERO · OTC · CIK 1870404 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/cero.md) · [Financials](/companies/cero/financials.md) · [Filings](/companies/cero/filings.md) · [Insiders](/companies/cero/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/cero/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $k | [1,800](/filings/0001213900-24-044805.md) | [1,193](/filings/0001213900-24-069055.md) | [1,278](/filings/0001213900-24-100303.md) | [1,018 d](/filings/0001213900-25-032134.md) | [2,714](/filings/0001213900-25-079898.md) | [1,774](/filings/0001213900-25-112619.md) | [2,908](/filings/0001213900-26-057753.md) | [2,754](/filings/0001213900-26-090030.md) | [2,386](/filings/0001213900-25-112619.md) | not reported | [2,338](/filings/0001213900-26-057753.md) | [1,736](/filings/0001213900-26-090030.md) |
| Operating income | $k | [(2,438)](/filings/0001213900-24-044805.md) | [(2,414)](/filings/0001213900-24-069055.md) | [(1,536)](/filings/0001213900-24-100303.md) | [(1,121) d](/filings/0001213900-25-032134.md) | [(5,148)](/filings/0001213900-25-079898.md) | [(4,402)](/filings/0001213900-25-112619.md) | [(4,951)](/filings/0001213900-26-057753.md) | [(4,724)](/filings/0001213900-26-090030.md) | [(4,363)](/filings/0001213900-25-112619.md) | not reported | [(4,846)](/filings/0001213900-26-057753.md) | [(3,846)](/filings/0001213900-26-090030.md) |
| Interest expense | $k | [(0.0)](/filings/0001213900-24-044805.md) | [(59.4)](/filings/0001213900-24-069055.md) | [(0.2)](/filings/0001213900-24-100303.md) | [(20.1) d](/filings/0001213900-25-032134.md) | [17.0](/filings/0001213900-24-069055.md) | [(4.4)](/filings/0001213900-24-100303.md) | not reported | not reported | not reported | not reported | [166](/filings/0001213900-26-057753.md) | [690](/filings/0001213900-26-090030.md) |
| Income tax | $k | not reported | [44.7](/filings/0001213900-23-066987.md) | [25.8](/filings/0001213900-23-085200.md) | [24.4 d](/filings/0001213900-24-029051.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $k | [(2,438)](/filings/0001213900-24-044805.md) | [(2,093)](/filings/0001213900-24-069055.md) | [(1,349)](/filings/0001213900-24-100303.md) | [(1,265) d](/filings/0001213900-25-032134.md) | [(2,449)](/filings/0001213900-25-112619.md) | [(4,228)](/filings/0001213900-25-112619.md) | [(5,106)](/filings/0001213900-26-090030.md) | [(5,417)](/filings/0001213900-26-090030.md) | [(4,856)](/filings/0001213900-25-112619.md) | [(4,541) d](/filings/0001213900-26-044040.md) | [(5,886)](/filings/0001213900-26-090030.md) | [(1,029)](/filings/0001213900-26-090030.md) |
| Diluted EPS | $ per share | [(0.27)](/filings/0001213900-24-044805.md) | [(0.23)](/filings/0001213900-24-069055.md) | [(0.15)](/filings/0001213900-24-100303.md) | not reported | [(302.32)](/filings/0001213900-25-079898.md) | [(170.22)](/filings/0001213900-25-112619.md) | [(31.82)](/filings/0001213900-26-057753.md) | [(61.71)](/filings/0001213900-26-090030.md) | [(9.10)](/filings/0001213900-25-112619.md) | not reported | [(0.20)](/filings/0001213900-26-057753.md) | [(0.70)](/filings/0001213900-26-090030.md) |
| Basic EPS | $ per share | [(0.27)](/filings/0001213900-24-044805.md) | [(0.23)](/filings/0001213900-24-069055.md) | [(0.15)](/filings/0001213900-24-100303.md) | not reported | [(302.32)](/filings/0001213900-25-079898.md) | [(170.22)](/filings/0001213900-25-112619.md) | [(31.82)](/filings/0001213900-26-057753.md) | [(61.71)](/filings/0001213900-26-090030.md) | [(9.10)](/filings/0001213900-25-112619.md) | not reported | [(0.20)](/filings/0001213900-26-057753.md) | [(0.70)](/filings/0001213900-26-090030.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | period not labelled (2024-02-14) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | FY2025 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $bn | [0.0](/filings/0001213900-24-029051.md) | not reported | [1.0](/filings/0001213900-24-044805.md) | [0.0](/filings/0001213900-24-069055.md) | [0.0](/filings/0001213900-24-100303.md) | [0.0](/filings/0001213900-25-032134.md) | [0.0](/filings/0001213900-25-044335.md) | [0.0](/filings/0001213900-26-090030.md) | [0.0](/filings/0001213900-25-112619.md) | [0.0](/filings/0001213900-26-044040.md) | [857](/filings/0001213900-26-057753.md) | [0.0](/filings/0001213900-26-090030.md) |
| Current assets | $bn | [0.0](/filings/0001213900-25-032134.md) | not reported | [0.0](/filings/0001213900-24-044805.md) | [0.0](/filings/0001213900-24-069055.md) | [0.0](/filings/0001213900-24-100303.md) | [0.0](/filings/0001213900-26-044040.md) | [0.0](/filings/0001213900-25-044335.md) | [0.0](/filings/0001213900-25-079898.md) | [0.0](/filings/0001213900-25-112619.md) | [0.0](/filings/0001213900-26-090030.md) | [0.0](/filings/0001213900-26-057753.md) | [0.0](/filings/0001213900-26-090030.md) |
| Total assets | $bn | [0.0](/filings/0001213900-25-032134.md) | not reported | [0.0](/filings/0001213900-24-044805.md) | [0.0](/filings/0001213900-24-069055.md) | [0.0](/filings/0001213900-24-100303.md) | [0.0](/filings/0001213900-26-044040.md) | [0.0](/filings/0001213900-25-044335.md) | [0.0](/filings/0001213900-25-079898.md) | [0.0](/filings/0001213900-25-112619.md) | [0.0](/filings/0001213900-26-090030.md) | [0.0](/filings/0001213900-26-057753.md) | [0.0](/filings/0001213900-26-090030.md) |
| Current liabilities | $bn | [0.0](/filings/0001213900-25-032134.md) | not reported | [0.0](/filings/0001213900-24-044805.md) | [0.0](/filings/0001213900-24-069055.md) | [0.0](/filings/0001213900-24-100303.md) | [0.0](/filings/0001213900-26-044040.md) | [0.0](/filings/0001213900-25-044335.md) | [0.0](/filings/0001213900-25-079898.md) | [0.0](/filings/0001213900-25-112619.md) | [0.0](/filings/0001213900-26-090030.md) | [0.0](/filings/0001213900-26-057753.md) | [0.0](/filings/0001213900-26-090030.md) |
| Total liabilities | $bn | [0.0](/filings/0001213900-25-032134.md) | not reported | [0.0](/filings/0001213900-24-044805.md) | [0.0](/filings/0001213900-24-069055.md) | [0.0](/filings/0001213900-24-100303.md) | [0.0](/filings/0001213900-26-044040.md) | [0.0](/filings/0001213900-25-044335.md) | [0.0](/filings/0001213900-25-079898.md) | [0.0](/filings/0001213900-25-112619.md) | [0.0](/filings/0001213900-26-090030.md) | [0.0](/filings/0001213900-26-057753.md) | [0.0](/filings/0001213900-26-090030.md) |
| Long-term debt | $bn | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-057753.md) | not reported |
| Shareholders' equity | $bn | [(0.0)](/filings/0001213900-25-032134.md) | [(0.0)](/filings/0001213900-26-044040.md) | [(0.0)](/filings/0001213900-24-044805.md) | [(0.0)](/filings/0001213900-24-069055.md) | [(0.0)](/filings/0001213900-24-100303.md) | [(0.0)](/filings/0001213900-26-090030.md) | [(0.0)](/filings/0001213900-26-090030.md) | [(0.0)](/filings/0001213900-26-090030.md) | [(0.0)](/filings/0001213900-25-112619.md) | [(0.0)](/filings/0001213900-26-090030.md) | [(0.0)](/filings/0001213900-26-090030.md) | [(0.0)](/filings/0001213900-26-090030.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q4 FY2022 (2022-12-31) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.2) d](/filings/0001213900-23-085200.md) | [(0.4) d](/filings/0001213900-24-029051.md) | [(0.2)](/filings/0001193125-23-143454.md) | [(0.9) d](/filings/0001213900-23-066987.md) | [(0.3) d](/filings/0001213900-23-085200.md) | [(0.2) d](/filings/0001213900-24-029051.md) | not reported | not reported | not reported | not reported | [2.8](/filings/0001213900-26-057753.md) | [(7.9) d](/filings/0001213900-26-090030.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.1](/filings/0001213900-26-090030.md) | [0.0 d](/filings/0001213900-25-079898.md) | [0.0 d](/filings/0001213900-25-112619.md) | [0.0 d](/filings/0001213900-26-044040.md) | [0.1](/filings/0001213900-26-057753.md) | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [27.8 d](/filings/0001213900-24-029051.md) | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q2 FY2025 (2024-06-30) | Q3 FY2025 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [9.1](/filings/0001213900-24-044805.md) | [9.1](/filings/0001213900-24-069055.md) | [9.1](/filings/0001213900-24-100303.md) | [0.0](/filings/0001213900-25-079898.md) | [0.0](/filings/0001213900-25-112619.md) | [0.2](/filings/0001213900-26-057753.md) | [0.5](/filings/0001213900-26-090030.md) | [1.3](/filings/0001213900-25-112619.md) | [28.8](/filings/0001213900-26-057753.md) | [42.2](/filings/0001213900-26-090030.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 71,630,992 at 2026-08-13, from the cover of the [10-Q filed 2026-08-14](/filings/0001213900-26-090030.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:49 ET. No prices; not investment advice.